Abecassis J-P, Ghazzar N, Peyromaure M, Giraud P
Réseau d'imagerie parisien, 2, villa Cœur-de-Vey, 75014 Paris, France.
Service de médecine nucléaire, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France.
Cancer Radiother. 2020 Aug;24(5):423-428. doi: 10.1016/j.canrad.2020.06.002. Epub 2020 Jun 30.
Prostate cancer is the most common malignant tumour and represents the third cause of cancer-mortality in men. The management of prostate cancer has dramatically changed over the last decades, mainly due to improvement of diagnostic modalities and development of new therapeutic strategies. Imaging plays a key role in all the steps of prostate cancer management. In recent years, magnetic resonance imaging (MRI) and positron-emission tomography (PET) - computed tomography (CT) have emerged as two major tools for the detection of prostate cancer, tumour staging and treatment choice. Both MRI and PET-CT - using choline or prostate-specific membrane antigen (PSMA) as radiotracer - have become mandatory. This article presents the contribution of the latest advances in these two imaging techniques of prostate cancer and their future developments.
前列腺癌是最常见的恶性肿瘤，是男性癌症死亡的第三大原因。在过去几十年中，前列腺癌的管理发生了巨大变化，这主要归功于诊断方式的改进和新治疗策略的发展。影像学在前列腺癌管理的所有环节中都起着关键作用。近年来，磁共振成像（MRI）和正电子发射断层扫描（PET）-计算机断层扫描（CT）已成为检测前列腺癌、肿瘤分期和治疗选择的两大主要工具。使用胆碱或前列腺特异性膜抗原（PSMA）作为放射性示踪剂的MRI和PET-CT都已成为必不可少的手段。本文介绍了这两种前列腺癌成像技术的最新进展及其未来发展。
